han 300 human
viruses that have no treatment, vaccine or antiviral, and there are only 62
drugs approved by the FDA for the treatment of six different viral
illnesses caused by hepatitis B and C, herpes, HIV, influenza, and
respiratory syncytial viruses. Of these, almost half are for the treatment
of HIV/AIDS. The remaining drugs offer treatments that target the other
five viruses. Therefore, identifying new molecular probes will promote the
discovery of new approaches for therapeutic intervention.
Southern Research was one of nine U.S.-based research facilities chosen
to participate in the six year program. The MLPCN will offer high
throughput screening (HTS) and probe development resources to public and
private researchers via the general NIH Program Announcement (PAR-08-035:
Solicitation of Assays for HTS in the Molecular Libraries Probed Production
Centers Network (MLPCN) (NOT-RM-08-022)
http://grants.nih.gov/grants/guide/notice-files/NOT- RM-08-022.html).
The eight other institutions who also received grants as part of the
Molecular Libraries Probe Production Center Network include:
-- Burnham Center for Chemical Genomics, Burnham Institute, La Jolla,
Calif.
-- Broad Institute Comprehensive Screening Center, Broad Institute,
Cambridge, Mass.
-- Comprehensive Center for Chemical Probe Discovery and Optimization
at Scripps Research Institute, Scripps Institute, San Diego, Calif.
-- Johns Hopkins Ion Channel Center, Johns Hopkins University,
Baltimore, Md.
-- NIH Chemical Genomics Center, NIH/NHGRI, Rockville, Md.
-- University of Kansas Specialized Chemistry Center, University of
Kansas, Lawrence, Kan.
-- University of New Mexico Center for Molecular Discovery, University
of New Mexico, Albuquerque, N.M.
-- Vanderbilt Specialized Chemistry Center for Accelerated Probe
Development, Vanderbilt University, Nashville, T
'/>"/>
SOURCE Southern Research Institute Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine technology :1.
Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals2.
New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis3.
Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment4.
The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research5.
K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains6.
Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists7.
Dallas Researchers Find Compression Stockings Improperly Used8.
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research9.
Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma10.
New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating, Often Fatal Disease11.
Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End